ProGem1: A phase I/II study of a first-in-class nucleotide, Acelarin, in patients with advanced solid tumors

被引：0

作者：

Ghazaly, Essam Ahmed

Rizzuto, Ivana

Gabra, Hani

Habib, Nagy A.

Leonard, Robert C. F.

Wasan, Harpreet

McGuigan, Christopher

Blagden, Sarah Patricia

机构：

[1] Queen Mary Univ London, Barts Canc Inst, Ctr Haematooncol, London, England

[2] Univ London Imperial Coll Sci Technol & Med, NIHR Wellcome Trust Imperial Clin Res Facil, London, England

[3] Univ London Imperial Coll Sci Technol & Med, Dept Oncol, London, England

[4] Cardiff Univ, Sch Pharm & Pharmaceut Sci, Cardiff CF10 3AX, S Glam, Wales

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.2531

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2531

引用

页数：1

共 50 条

[21] First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors [J].

Baird, Richard D. ;

Linossi, Constanza ;

Middleton, Mark ;

Lord, Simon ;

Harris, Adrian ;

Rodon, Jordi ;

Zitt, Christof ;

Fiedler, Ulrike ;

Dawson, Keith M. ;

Leupin, Nicolas ;

Stumpp, Michael T. ;

Harstrick, Andreas ;

Azaro, Analia ;

Fischer, Stefanie ;

Omlin, Aurelius .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (02) :145-+

[22] A phase I trial of GRN163L (GRN), a first-in-class telomerase inhibitor, in advanced solid tumors [J].

Ratain, M. J. ;

Benedetti, F. M. ;

Janisch, L. ;

Khor, S. ;

Schilsky, R. L. ;

Cohen, E. E. ;

Maitland, M. L. ;

Elias, L. ;

LoRusso, P. M. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[23] Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors [J].

Chen, Jian Jenny ;

Vincent, Melanie Y. ;

Shepard, Dale ;

Peereboom, David ;

Mahalingam, Devalingam ;

Battiste, James ;

Patel, Manish R. ;

Juric, Dejan ;

Wen, Patrick Y. ;

Bullock, Andrea ;

Selfridge, Jennifer Eva ;

Pant, Shubham ;

Liu, Joyce ;

Li, Wendy ;

Fyfe, Susanne ;

Wang, Suming ;

Zota, Victor ;

Mahoney, James ;

Watnick, Randolph S. ;

Cieslewicz, Michael ;

Watnick, Jing .

COMMUNICATIONS MEDICINE, 2024, 4 (01)

[24] A first-in-human, first-in-class, phase (ph) I study of systemic Hedgehog (Hh) pathway antagonist, GDC-0449, in patients (pts) with advanced solid tumors [J].

LoRusso, P. M. ;

Rudin, C. M. ;

Borad, M. J. ;

Vernillet, L. ;

Darbonne, W. C. ;

Mackey, H. ;

DiMartino, J. F. ;

de Sauvage, F. ;

Low, J. A. ;

Von Hoff, D. D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[25] A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors. [J].

Gabrail, Nashat Y. ;

Hamilton, Erika P. ;

Elias, Anthony D. ;

Rimawi, Mothaffar F. ;

Li, Chao ;

Corvez, Maria Margarita ;

Li, Wei ;

Feng, Ying ;

Wei, Jiao ;

Greene, Stephanie ;

Patterson, John ;

Zeng, Qingping ;

Hui, Ai-Min .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[26] First-in-human, phase I study of CBP-1008, a first-in-class bispecific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors [J].

Li, Ning ;

Gong, Jifang ;

Zhang, Jian ;

Liu, Dan ;

Chen, Yaqing ;

Zhang, Youzhong ;

Huang, Yi ;

Wang, Jing ;

Tang, Jie ;

Li, Guiling ;

Wang, Ying ;

Wu, Junyan ;

Luo, Suxia ;

Lou, Ge ;

Duan, Wei ;

Huang, Robert ;

Xu, Mo ;

Hu, Xichun ;

Wu, Lingying ;

Shen, Lin .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

[27] First-in-human, phase I study of CBP-1008, a first-in-class bispecific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors [J].

Li, N. ;

Gong, J. ;

Zhang, J. ;

Liu, D. ;

Chen, Y. ;

Zhang, Y. ;

Huang, Y. ;

Wang, J. ;

Tang, J. ;

Li, G. ;

Wang, Y. ;

Wu, J. ;

Luo, S. ;

Lou, G. ;

Duan, W. ;

Huang, R. ;

Xu, M. ;

Hu, X. ;

Wu, L. ;

Shen, L. .

ANNALS OF ONCOLOGY, 2024, 35 :S589-S589

[28] A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors. [J].

Pauff, James Michael ;

Papadopoulos, Kyriakos P. ;

Janku, Filip ;

Turk, Anita Ahmed ;

Goyal, Lipika ;

Shroff, Rachna T. ;

Shimizu, Toshio ;

Ikeda, Masafumi ;

Azad, Nilofer Saba ;

Cleary, James M. ;

Peters, Mary Linton Bounetheau ;

Borad, Mitesh J. ;

Jaeckle, Kurt A. ;

Kizilbash, Sani Haider ;

Tupper, Rebecca ;

Furin, Carrie E. ;

Hanley, Matthew P. ;

Hill, Elizabeth Goodwin ;

Xu Xiaojian ;

Harding, James J. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)

[29] A Phase 1 dose escalation study of TACH101, a first-in-class KDM4 inhibitor for advanced solid tumors [J].

Tsimberidou, Apostolia ;

Vandross, Andrae L. ;

Sommerhalder, David ;

Joseph, Charmaine ;

Chandhasin, Chandtip ;

Perabo, Frank ;

Clarke, Michael F. .

MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)

[30] PHASE I AND PHARMACOKINETICS/PHARMACODYNAMICS (PK/PD) STUDY OF RO5126766, A FIRST-IN-CLASS DUAL RAF/MEK INHIBITOR, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS [J].

Honda, K. ;

Yamamoto, N. ;

Nokihara, H. ;

Yamada, Y. ;

Tamura, Y. ;

Asahina, H. ;

Suzuki, S. ;

Yamazaki, N. ;

Ogita, Y. ;

Hasegawa, W. ;

Matsuoka, M. ;

Tamura, T. .

ANNALS OF ONCOLOGY, 2012, 23 :110-110

← 1 2 3 4 5 →